331 related articles for article (PubMed ID: 18698037)
1. HER3 is a determinant for poor prognosis in melanoma.
Reschke M; Mihic-Probst D; van der Horst EH; Knyazev P; Wild PJ; Hutterer M; Meyer S; Dummer R; Moch H; Ullrich A
Clin Cancer Res; 2008 Aug; 14(16):5188-97. PubMed ID: 18698037
[TBL] [Abstract][Full Text] [Related]
2. Toward the prognostic significance and therapeutic potential of HER3 receptor tyrosine kinase in human colon cancer.
Beji A; Horst D; Engel J; Kirchner T; Ullrich A
Clin Cancer Res; 2012 Feb; 18(4):956-68. PubMed ID: 22142822
[TBL] [Abstract][Full Text] [Related]
3. ErbB-3 predicts survival in ovarian cancer.
Tanner B; Hasenclever D; Stern K; Schormann W; Bezler M; Hermes M; Brulport M; Bauer A; Schiffer IB; Gebhard S; Schmidt M; Steiner E; Sehouli J; Edelmann J; Läuter J; Lessig R; Krishnamurthi K; Ullrich A; Hengstler JG
J Clin Oncol; 2006 Sep; 24(26):4317-23. PubMed ID: 16896008
[TBL] [Abstract][Full Text] [Related]
4. High expression of HER3 is associated with a decreased survival in gastric cancer.
Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
[TBL] [Abstract][Full Text] [Related]
6. HER3 expression in cutaneous tumors.
Wimmer E; Kraehn-Senftleben G; Issing WJ
Anticancer Res; 2008; 28(2A):973-9. PubMed ID: 18507044
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.
Begnami MD; Fukuda E; Fregnani JH; Nonogaki S; Montagnini AL; da Costa WL; Soares FA
J Clin Oncol; 2011 Aug; 29(22):3030-6. PubMed ID: 21709195
[TBL] [Abstract][Full Text] [Related]
8. Loss of retinoblastoma tumor suppressor protein makes human breast cancer cells more sensitive to antimetabolite exposure.
Derenzini M; Donati G; Mazzini G; Montanaro L; Vici M; Ceccarelli C; Santini D; Taffurelli M; Treré D
Clin Cancer Res; 2008 Apr; 14(7):2199-209. PubMed ID: 18381962
[TBL] [Abstract][Full Text] [Related]
9. Novel role for RGS1 in melanoma progression.
Rangel J; Nosrati M; Leong SP; Haqq C; Miller JR; Sagebiel RW; Kashani-Sabet M
Am J Surg Pathol; 2008 Aug; 32(8):1207-12. PubMed ID: 18580492
[TBL] [Abstract][Full Text] [Related]
10. The role of RhoC in growth and metastatic capacity of melanoma.
Boone B; Van Gele M; Lambert J; Haspeslagh M; Brochez L
J Cutan Pathol; 2009 Jun; 36(6):629-36. PubMed ID: 19222696
[TBL] [Abstract][Full Text] [Related]
11. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
12. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.
Yu J; Cheng YY; Tao Q; Cheung KF; Lam CN; Geng H; Tian LW; Wong YP; Tong JH; Ying JM; Jin H; To KF; Chan FK; Sung JJ
Gastroenterology; 2009 Feb; 136(2):640-51.e1. PubMed ID: 19084528
[TBL] [Abstract][Full Text] [Related]
13. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma.
Hino R; Kabashima K; Kato Y; Yagi H; Nakamura M; Honjo T; Okazaki T; Tokura Y
Cancer; 2010 Apr; 116(7):1757-66. PubMed ID: 20143437
[TBL] [Abstract][Full Text] [Related]
14. Reduced hGC-1 protein expression is associated with malignant progression of colon carcinoma.
Liu W; Liu Y; Zhu J; Wright E; Ding I; Rodgers GP
Clin Cancer Res; 2008 Feb; 14(4):1041-9. PubMed ID: 18281536
[TBL] [Abstract][Full Text] [Related]
15. Nucleolin protein expression in cutaneous melanocytic lesions.
Mourmouras V; Cevenini G; Cosci E; Epistolato MC; Biagioli M; Barbagli L; Luzi P; Mannucci S; Miracco C
J Cutan Pathol; 2009 Jun; 36(6):637-46. PubMed ID: 19515042
[TBL] [Abstract][Full Text] [Related]
16. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
17. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays.
Nambiar S; Mirmohammadsadegh A; Doroudi R; Gustrau A; Marini A; Roeder G; Ruzicka T; Hengge UR
Arch Dermatol; 2005 Feb; 141(2):165-73. PubMed ID: 15724012
[TBL] [Abstract][Full Text] [Related]
18. c-Met is a potentially new therapeutic target for treatment of human melanoma.
Puri N; Ahmed S; Janamanchi V; Tretiakova M; Zumba O; Krausz T; Jagadeeswaran R; Salgia R
Clin Cancer Res; 2007 Apr; 13(7):2246-53. PubMed ID: 17404109
[TBL] [Abstract][Full Text] [Related]
19. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of nuclear ING3 expression in human cutaneous melanoma.
Wang Y; Dai DL; Martinka M; Li G
Clin Cancer Res; 2007 Jul; 13(14):4111-6. PubMed ID: 17634537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
